Abstract

Ixekizumab is a humanized monoclonal antibody that specifically inhibits IL-17A. It has been approved for the treatment of adult and pediatric psoriasis, psoriatic arthritis and axial spondyloarthropathies by the US FDA and the EMA. Phase III trials, post hoc analyses and real-life data have reported its efficacy, effectiveness and safety. This review summarizes the latest evidence on the clinical efficacy, pharmacology and safety profile of ixekizumab for the treatment of moderate-to-severe psoriasis. A literature search was performed for articles published through December 2022. Ixekizumab is one of the most efficacious biologics for psoriasis, with a rapid onset of response, favorable long-term outcomes and an adequate safety profile.

Plain language summary

Ixekizumab is a biologic therapy, a type of disease treatment that uses substances from living organisms, currently available for the treatment of psoriasis. It works as an antibody directed against a molecule that causes inflammation, named IL-17A, which is essential for the development of psoriasis lesions. Ixekizumab has been approved by the US FDA and EMA for the treatment of psoriasis, psoriatic arthritis and axial spondyloarthropathies in adults and children. Its effectiveness and safety have been widely proven in multiple clinical trials and real-life settings. This review summarizes the latest evidence on the clinical efficacy, pharmacology and safety profile of ixekizumab for the treatment of moderate-to-severe psoriasis.

Tweetable abstract

Ixekizumab, an IL-17A inhibitor, is one of the most effective biologic treatments for psoriasis, with rapid onset of response, favorable long-term outcomes and a proper safety profile. Check our latest review to learn more about it. #psoriasis #ixekizumab #IL-17 #biologic #treatment #FDA #EMA #dermatology

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Boehncke W-H, Schön MP. Psoriasis. Lancet 386(9997), 983–994 (2015).
Medline CASGoogle Scholar
2. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol. 61(3), 451–485 (2009).
Medline CASGoogle Scholar
3. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 20(6), 1475 (2019).
Medline CASGoogle Scholar
4. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol. 55(3), 379–390 (2018).
Medline CASGoogle Scholar
5. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity 50(4), 892–906 (2019).
Medline CASGoogle Scholar
6. Krueger JG, Fretzin S, Suárez-Fariñas M et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol. 130(1), 145–154.e9 (2012).
Medline CASGoogle Scholar
7. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131(3), 677–687 (2011).
Medline CASGoogle Scholar
8. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52ra72 (2010).
MedlineGoogle Scholar
9. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int. J. Mol. Sci. 18(11), 2297 (2017).
MedlineGoogle Scholar
10. Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs 81(15), 1751–1762 (2021).
Medline CASGoogle Scholar
11. Goepfert A, Lehmann S, Wirth E, Rondeau J-M. The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties. Sci. Rep. 7(1), 8906 (2017).
MedlineGoogle Scholar
12. Puig L. The safety of ixekizumab in psoriasis drug therapy. Expert Opin. Drug Saf. 19(2), 117–130 (2020).
Medline CASGoogle Scholar
13. Leonardi C, Matheson R, Zachariae C et al. Anti–interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190–1199 (2012).
Medline CASGoogle Scholar
14. Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. 375(4), 345–356 (2016). • UNCOVER-3 was the first phase III clinical trial to demonstrate ixekizumab's efficacy and safety for patients with moderate-to-severe plaque psoriasis.
Medline CASGoogle Scholar
15. Griffiths CEM, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386(9993), 541–551 (2015).
Medline CASGoogle Scholar
16. Paul C, Griffiths CEM, van de Kerkhof PCM et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: results from IXORA-S, a phase 3 study. J. Am. Acad. Dermatol. 80(1), 70–79.e3 (2019).
Medline CASGoogle Scholar
17. Reich K, Pinter A, Lacour JP et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br. J. Dermatol. 177(4), 1014–1023 (2017).
Medline CASGoogle Scholar
18. Blauvelt A, Leonardi C, Elewski B et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br. J. Dermatol. 184(6), 1047–1058 (2021).
Medline CASGoogle Scholar
19. Reich K, Augustin M, Thaçi D et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br. J. Dermatol. 182(4), 869–879 (2020).
Medline CASGoogle Scholar
20. Callis Duffin K, Bagel J, Bukhalo M et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J. Eur. Acad. Dermatol. Venereol. 31(1), 107–113 (2017).
MedlineGoogle Scholar
21. Tham L-S, Tang C-C, Choi S-L, Satterwhite JH, Cameron GS, Banerjee S. Population exposure–response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. J. Clin. Pharmacol. 54(10), 1117–1124 (2014).
Medline CASGoogle Scholar
22. Liu L, Kikly K, Lu J et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J. Inflamm. Res. 19(9), 39–50 (2016).
Google Scholar
23. Shelton SK, Bai SR, Jordan JK, Sheehan AH. Ixekizumab: a review of its use for the management of moderate to severe plaque psoriasis. Ann. Pharmacother. 53(3), 276–284 (2019).
Medline CASGoogle Scholar
24. Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84(5), 548–558 (2008).
Medline CASGoogle Scholar
25. Reich K, Jackson K, Ball S et al. Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis. J. Invest. Dermatol. 138(10), 2168–2173 (2018).
Medline CASGoogle Scholar
26. Genovese MC, van den Bosch F, Roberson SA et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62(4), 929–939 (2010).
Medline CASGoogle Scholar
27. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124(5), 1022–1030.e395 (2009).
Medline CASGoogle Scholar
28. Gordon KB, Leonardi CL, Lebwohl M et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 71(6), 1176–1182 (2014).
Medline CASGoogle Scholar
29. Zachariae C, Gordon K, Kimball AB et al. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J. Am. Acad. Dermatol. 79(2), 294–301.e6 (2018).
Medline CASGoogle Scholar
30. Zhu B, Edson-Heredia E, Cameron GS et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 169(6), 1337–1341 (2013).
Medline CASGoogle Scholar
31. Saeki H, Nakagawa H, Nakajo K et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J. Dermatol. 44(4), 355–362 (2017).
Medline CASGoogle Scholar
32. Papp KA, Leonardi CL, Blauvelt A et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br. J. Dermatol. 178(3), 674–681 (2018).
Medline CASGoogle Scholar
33. Papp KA, Leonardi CL, Blauvelt A et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br. J. Dermatol. 178(3), 674–681 (2018).
Medline CASGoogle Scholar
34. Blauvelt A, Gooderham M, Iversen L et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J. Am. Acad. Dermatol. 77(5), 855–862 (2017).
Medline CASGoogle Scholar
35. Leonardi C, Maari C, Philipp S et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J. Am. Acad. Dermatol. 79(5), 824–830.e2 (2018).
Medline CASGoogle Scholar
36. Blauvelt A, Lebwohl MG, Mabuchi T et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J. Am. Acad. Dermatol. 85(2), 360–368 (2021).
Medline CASGoogle Scholar
37. Gottlieb AB, Lacour J-P, Korman N et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J. Eur. Acad. Dermatol. Venereol. 31(4), 679–685 (2017).
Medline CASGoogle Scholar
38. Blauvelt A, Papp KA, Sofen H et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J. Eur. Acad. Dermatol. Venereol. 31(6), 1004–1013 (2017).
Medline CASGoogle Scholar
39. Kimball AB, Luger T, Gottlieb A et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J. Am. Acad. Dermatol. 75(6), 1156–1161 (2016).
Medline CASGoogle Scholar
40. Leonardi CL, Blauvelt A, Sofen HL et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J. Eur. Acad. Dermatol. Venereol. 31(9), 1483–1490 (2017).
Medline CASGoogle Scholar
41. Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 31(7), 1196–1207 (2017).
Medline CASGoogle Scholar
42. Kemény L, Berggren L, Dossenbach M, Dutronc Y, Paul C. Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. J. Dermatol. Treat. 30(1), 19–26 (2019).
Medline CASGoogle Scholar
43. van de Kerkhof P, Guenther L, Gottlieb AB et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J. Eur. Acad. Dermatol. Venereol. 31(3), 477–482 (2017).
MedlineGoogle Scholar
44. Menter A, Warren RB, Langley RG et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J. Eur. Acad. Dermatol. Venereol. 31(10), 1686–1692 (2017).
Medline CASGoogle Scholar
45. Reich K, Leonardi C, Lebwohl M et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J. Dermatol. Treat. 28(4), 282–287 (2017).
Medline CASGoogle Scholar
46. Guenther L, Bleakman A, Weisman J et al. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm. Venereol. 100(1), 1–9 (2020).
Google Scholar
47. Paul C, Guenther L, Torii H et al. Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. J. Eur. Acad. Dermatol.Venereol. 32(1), 68–72 (2018).
Medline CASGoogle Scholar
48. Paller AS, Seyger MMB, Alejandro Magariños G et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br. J. Dermatol. 183(2), 231–241 (2020).
Medline CASGoogle Scholar
49. Paller AS, Seyger MMB, Magariños GA et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 158(5), 533–541 (2022). • The IXORA-PEDS was the first clinical trial to demonstrate ixekizumab's efficacy and safety for pediatric patients with moderate-to-severe plaque psoriasis.
MedlineGoogle Scholar
50. Blauvelt A, Papp K, Gottlieb A et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br. J. Dermatol. 182(6), 1348–1358 (2020).
Medline CASGoogle Scholar
51. Blauvelt A, Leonardi C, Elewski B et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br. J. Dermatol. 184(6), 1047–1058 (2021).
Medline CASGoogle Scholar
52. Warren RB, Brnabic A, Saure D et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br. J. Dermatol. 178(5), 1064–1071 (2018).
Medline CASGoogle Scholar
53. Díaz Acedo R, Galvan Banqueri M, Márquez Saavedra E. Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis. J. Clin. Pharm. Ther. 45(4), 715–721 (2020).
MedlineGoogle Scholar
54. Craig S, Warren RB. Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin. Biol. Ther. 20(6), 549–557 (2020).
Medline CASGoogle Scholar
55. Deza G, Notario J, Lopez-Ferrer A et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J. Eur. Acad. Dermatol.Venereol. 33(3), 553–559 (2019).
Medline CASGoogle Scholar
56. Chiricozzi A, Burlando M, Caldarola G et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am. J. Clin. Dermatol. 21(3), 441–447 (2020).
MedlineGoogle Scholar
57. Magdaleno-Tapial J, Carmena-Ramón R, Valenzuela-Oñate C et al. Eficacia y seguridad de ixekizumab en la práctica clínica habitual: estudio retrospectivo bicéntrico. Actas Dermosifiliogr. 110(7), 585–589 (2019).
Medline CASGoogle Scholar
58. Gönülal M, Altunay İK, Doğan S, Türkmen M, Balcı DD, Öztürkcan S. Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: clinical data from a real-world experience. Dermatol. Ther. 35(12), e15955 (2022).
Medline CASGoogle Scholar
59. Georgakopoulos JR, Phung M, Ighani A, Yeung J. Ixekizumab (interleukin 17A antagonist): 12-week efficacy and safety outcomes in real-world clinical practice. J. Cutan. Med. Surg. 23(2), 174–177 (2019).
Medline CASGoogle Scholar
60. Malagoli P, Dapavo P, Pavia G et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis). Dermatol. Ther. 35(8), e15608 (2022).
Medline CASGoogle Scholar
61. Caldarola G, Chiricozzi A, Megna M et al. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opin. Biol. Ther. 23(4), 365–370 (2023).
Medline CASGoogle Scholar
62. Rivera R, Velasco M, Vidal D et al. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: a Spanish multicentre retrospective study. Dermatol. Ther. 33(6), e14066 (2020).
Medline CASGoogle Scholar
63. Cariti C, Dapavo P, Mastorino L et al. Comparison of secukinumab and ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients. J. Eur. Acad. Dermatol.Venereol. 36(3), e233–e235 (2022).
Medline CASGoogle Scholar
64. Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 35(9), e15667 (2022).
Medline CASGoogle Scholar
65. Dapavo P, Siliquini N, Mastorino L et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J. Dermatolog. Treat. 33(4), 2352–2357 (2022).
Medline CASGoogle Scholar
66. Blauvelt A, Shi N, Burge R et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J. Am. Acad. Dermatol. 82(4), 927–935 (2020).
Medline CASGoogle Scholar
67. Blauvelt A, Shi N, Burge R et al. Comparison of real-world treatment patterns among psoriasis patients treated with ixekizumab or adalimumab. Patient Prefer. Adher. 14, 517–527 (2020).
MedlineGoogle Scholar
68. Iznardo H, Vilarrasa E, López-Ferrer A, Puig L. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br. J. Dermatol. 185(3), 660–662 (2021).
Medline CASGoogle Scholar
69. Blauvelt A, Shi N, Somani N et al. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. J. Am. Acad. Dermatol. 86(3), 581–589 (2022).
Medline CASGoogle Scholar
70. van Muijen ME, Thomas SE, Groenewoud HMM et al. Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort. Acta Derm. Venereol. 16(102), adv00712 (2022). •• This article provides knowledge of the relative effectiveness of biologic therapies in daily practice, comparing six biologics for psoriasis (etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab).
Google Scholar
71. Pinter A, Puig L, Schäkel K et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J. Eur. Acad. Dermatol.Venereol. 36(11), 2087–2100 (2022).
MedlineGoogle Scholar
72. Li Y, Yu Y, Wang Y et al. Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period. Eur. J. Dermatol. 32(5), 618–622 (2022).
Medline CASGoogle Scholar
73. Armstrong A, Paul C, Puig L et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol.Ther. (Heidelb.) 10(1), 133–150 (2020).
MedlineGoogle Scholar
74. Strober B, Leonardi C, Papp KA et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J. Am. Acad. Dermatol. 76(3), 432–440.e17 (2017).
Medline CASGoogle Scholar
75. Langley RG, Kimball AB, Nak H et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J. Eur. Acad. Dermatol.Venereol. 33(2), 333–339 (2019).
Medline CASGoogle Scholar
76. Griffiths CEM, Gooderham M, Colombel JF et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatol. Ther. (Heidelb.) 12(6), 1431–1446 (2022). •• This article is the latest integrated safety analysis of ixekizumab for psoriasis treatment in adult patients with up to 5 years of exposure, reporting long-term results assessed from 17 randomized trials.
MedlineGoogle Scholar
77. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br. J. Dermatol. 177(1), 47–62 (2017).
Medline CASGoogle Scholar
78. Facheris P, Valenti M, Pavia G et al. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab. Int. J. Dermatol. 59(8), e267–e268 (2020).
Medline CASGoogle Scholar
79. Güder S, Güder H. The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab. Dermatol. Ther. 34(2), e14894 (2021).
Medline CASGoogle Scholar
80. Shear NH, Paul C, Blauvelt A et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J. Drugs Dermatol. 17(2), 200–206 (2018).
Medline CASGoogle Scholar
81. Chabra S, Gill BJ, Gallo G et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv. Ther. 39(6), 2862–2872 (2022). • Two clinical trials evaluated injection site pain, bioequivalence and overall safety of the novel citrate-free formulation of ixekizumab.
Medline CASGoogle Scholar
82. Fu Y, Lee C-H, Chi C-C. Association of psoriasis with inflammatory bowel disease. JAMA Dermatol. 154(12), 1417 (2018).
MedlineGoogle Scholar
83. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12), 1693–1700 (2012).
Medline CASGoogle Scholar
84. Petitpain N, D'Amico F, Yelehe-Okouma M et al. IL-17 Inhibitors and inflammatory bowel diseases: a postmarketing study in Vigibase. Clin. Pharmacol. Ther. 110(1), 159–168 (2021).
Medline CASGoogle Scholar
85. Reich K, Leonardi C, Langley RG et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J. Am. Acad. Dermatol. 76(3), 441–448.e2 (2017).
Medline CASGoogle Scholar
86. Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 16(3), 185–196 (2019).
Medline CASGoogle Scholar
87. Wright S, Alloo A, Strunk A, Garg A. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors. J. Am. Acad. Dermatol. 83(2), 382–387 (2020).
Medline CASGoogle Scholar
88. Burisch J, Eigner W, Schreiber S et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLOS ONE 15(5), e0233781 (2020).
Medline CASGoogle Scholar
89. Caron B, Jouzeau J-Y, Miossec P et al. Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opin. Drug Saf. 21(2), 223–239 (2022).
Medline CASGoogle Scholar
90. Valenti M, Pavia G, Gargiulo L et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single-center real-life population. J. Dermatolog. Treat. 33(3), 1638–1642 (2022).
Medline CASGoogle Scholar
91. Rusiñol L, Camiña-Conforto G, Puig L. Biologic treatment of psoriasis in oncologic patients. Expert Opin. Biol. Ther. 22(12), 1567–1578 (2022).
Medline CASGoogle Scholar
92. Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population. JAMA Dermatol. 152(1), 73 (2016).
MedlineGoogle Scholar
93. Griffiths CEM, Fava M, Miller AH et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother. Psychosom. 86(5), 260–267 (2017).
MedlineGoogle Scholar
94. Taltz^®, package insert. Eli Lilly and Company, IN, USA. https://pi.lilly.com/us/taltz-uspi.pdf
Google Scholar
95. Miller J, Puravath AP, Orbai A-M. Ixekizumab for psoriatic arthritis: safety, efficacy, and patient selection. J. Inflamm. Res. 14, 6975–6991 (2021).
Medline CASGoogle Scholar
96. Harrison SR, Marzo-Ortega H. Ixekizumab: an IL-17A inhibitor for the treatment of axial spondylarthritis. Expert. Rev. Clin. Immunol. 17(10), 1059–1071 (2021).
Medline CASGoogle Scholar
97. Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J. Am. Acad. Dermatol. 79(1), 135–144.e7 (2018).
Medline CASGoogle Scholar
98. Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J. Dermatolog. Treat. 29(6), 569–578 (2018).
Medline CASGoogle Scholar
99. Armstrong AW, Betts KA, Signorovitch JE et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr. Med. Res. Opin. 34(7), 1325–1333 (2018).
MedlineGoogle Scholar
100. Mumolo MG, Bertani L, Ceccarelli L et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J. Gastroenterol. 24(33), 3681–3694 (2018).
Medline CASGoogle Scholar
101. Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn's-like disease in a patient exposed to anti-interleukin-17 blockade (ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 19(1), 162 (2019).
MedlineGoogle Scholar

Vol. 15, No. 15

Metrics

Downloaded 86 times

History

Received 22 January 2023

Accepted 20 July 2023

Published online 23 August 2023

Published in print October 2023

Information

Keywords

Author contributions

All authors declare to have contributed to the conception and design of the article, the writing of the draft, the critical review of the intellectual content and the final approval of the version presented.

Financial & competing interests disclosure

L Puig has received consultancy/speaker's honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium

Abstract

Plain language summary

Tweetable abstract

References